Taxillus chinensis

Synopsis

Taxillus chinensis (DC.) Danser — Encyclopedic Reference

1. Identity

Botanical and Nomenclatural Names

Taxillus chinensis (DC.) Danser — known in Chinese as Sangjisheng (桑寄生) — is a member of the family Loranthaceae. The plant drug derived from it is officially denominated Taxilli Herba and is included in the 2020 Edition of the Chinese Pharmacopoeia. It belongs to the order Santalales and the genus Taxillus Van Tiegh. The species epithet commemorates its primary geographic distribution in China; the authorial citation "(DC.)" refers to the Swiss botanist Augustin Pyramus de Candolle, who first described the taxon, with the Dutch botanist S.J. Danser subsequently assigning it to the genus Taxillus. In the older literature the plant is also encountered under synonyms relating to the broader genus Loranthus, and in Chinese-language sources as Sang Ji Sheng (桑寄生), San Ji Sheng, or simply "loranthus."

Biological Nature and Geographic Distribution

The hemiparasitic Taxillus chinensis is a root-parasitizing medicinal plant that retains photosynthetic ability, a trait lost in many other fully parasitic plants. It is predominantly found in East Asia, mainly in China, and belongs to the family Loranthaceae. It is commonly found in alpine and arid areas, mainly in southern and southwestern China, such as Guangxi, Fujian, Taiwan, Yunnan, Guangdong, and Hong Kong. In addition, it is distributed in several Southeast Asian nations, such as Malaya, Vietnam, Thailand, Laos, Cambodia, Borneo, and the Philippines.

T. chinensis is a hemi-parasitic plant that is more likely to be parasitic on medium and large trees, such as willow (Salix babylonica), maple poplar (Pterocarya stenoptera), and plane trees (Platanus acerifolia). The parasitic position is usually at half the height of the tree or higher. Recorded hosts also include Glyptostrobus pensilis, Hevea brasiliensis, Dimocarpus longan, and Moraceae spp. The spread of T. chinensis is mainly dependent on birds, which feed on its fruits and disperse its seeds in various host plants.

T. chinensis is a perennial hemiparasitic plant that is difficult to propagate artificially because of its low parasitic rate. Successful parasitism involves fusing plant tissues and connecting the vasculature to the host vasculature, building a physiological bridge that efficiently withdraws water, sugars, and nutrients from the host.

Medicinal Part and Common Preparations

The dried stems and leafy branches of T. chinensis are commonly used as materials for traditional Chinese medicine and are known as "Sang Ji Sheng" in China. Preparations take several forms: raw dried herb for decoction is the most traditional form; the plant also appears in standardized pills, granules, and extracts. T. chinensis is traditionally used to treat various diseases, including joint swelling and pain, rheumatism, threatened abortion, stroke, and hypertension. The Duhuo Jisheng, Qisang Yigan, and Sangge Jiangzhi pills, among other preparations, have been widely used in traditional prescriptions and have shown good clinical effects.

2. Traditional and Historical Use

Origins in Chinese Medicine

T. chinensis carries traditional functions of "dispelling wind dampness, strengthening bones and muscles, and preventing miscarriage." Since the Eastern Han dynasty (approximately 25–220 CE), it has been used for the treatment of rheumatoid arthritis, arthralgia, threatened abortion, and hypertension. This makes it one of the longer-documented medicinal plants in the Chinese materia medica, with an unbroken record of use spanning roughly two millennia. The earliest canonical reference to Sangjisheng appears in the Shennong Bencao Jing (Divine Farmer's Classic of Materia Medica), which is considered to date from the Eastern Han era, and subsequent generations of physicians continued to elaborate its indications.

Host-Specific Folk Applications

Owing to the parasitic characteristics of Loranthaceae plants, T. chinensis from different hosts is used to treat various diseases in folk medicine. For example, "Southern Yunnan Materia Medica" (AD 1436) records that T. chinensis parasitizing Styphnolobium japonicum (L.) Schott can treat intestinal sub-wind blood syndrome, hemorrhoids, and blood leakage; T. chinensis parasitizing Morus alba L. can treat muscle and collateral obstruction and wind-cold-dampness arthralgia. This host-specific differentiation of therapeutic use reflects a sophisticated empirical understanding, likely grounded in the observable differences in plant chemistry arising from different host species.

Traditional Indications Summary

In traditional clinical application, Taxillus chinensis has the functions of tonifying the liver and kidney, dispelling rheumatism, strengthening bones and muscles, nourishing blood, preventing miscarriage, and lowering blood pressure.
It has been used in various traditional Chinese medicine prescriptions for the treatment of rheumatism, threatened abortion, hypertension, angina pectoris, stroke, and arrhythmia for many years in China.

Duhuo Jisheng Decoction — A Key Traditional Formula

T. chinensis is a named ingredient in the classical multi-herb decoction Duhuo Jisheng (獨活寄生湯), originally compiled by the Tang dynasty physician Sun Simiao in his Beiji Qianjin Yaofang. This formula is composed of Angelica pubescens (Duhuo), Asarum heterotropoides (Xixin), Saposhnikovia divaricata (Fangfeng), Neolitsea cassia (Rougui), Gentiana macrophylla (Qinjiao), Taxillus chinensis (Sangjisheng), Eucommia ulmoides (Duzhong), Cyathula officinalis (Chuanniuxi), Paeonia lactiflora (Baishao), Rehmannia glutinosa (Dihuang), Angelica sinensis (Danggui), Panax ginseng (Renshen), Conioselinum anthriscoides 'Chuanxiong' (Chuanxiong), Smilax glabra (Fuling), and Glycyrrhiza glabra (Gancao). This decoction, including Sangjisheng (the dried twig of Taxillus chinensis), has been shown to combat cold and dampness and is a commonly considered prescription for the treatment of rheumatism.

3. Key Constituents and Active Compounds

Overview of Phytochemistry

To date, approximately 110 chemical constituents have been identified in T. chinensis, including flavonoids, phenolic acids, phenylpropanoids, tannins, glycosides, amino acids, and nucleosides. The main chemical constituents are flavonoids, such as quercetin, quercitrin, rutin, avicularin, and small amounts of d-catechol, mainly dihydroflavones, flavones, and flavonolosides, which are the current research hotspots. Flavonoids are considered the most vital bioactive ingredients in T. chinensis.

Flavonoids

Flavonoids constitute the most extensively characterized chemical class in T. chinensis. Among isolated compounds, quercetin has been widely studied and is the quality control index stipulated by the pharmacopoeia. Beyond quercetin, the flavonoid profile includes quercitrin (quercetin-3-rhamnoside), rutin (quercetin-3-rutinoside), avicularin, and dihydromyricetin, among others. Flavonoids were recommended as the inspection indicators in the quality evaluation reports, mainly focusing on the quantitative determination of quercetin, quercitrin, and avicularin.

A metabolomics study using ultra-pressure liquid chromatography coupled with tandem mass spectrometry (UPLC-MS) demonstrated that the total flavonoid content (up to 30.08 mg/g) in Taxillus chinensis growing on Morus alba was significantly higher than in specimens growing on Liquidambar formosana or Clausena lansium (p < 0.01).

Host-Dependent Variation in Chemical Composition

A particularly notable feature of T. chinensis phytochemistry is its dependence on the host plant. The metabolic activity of the parasitic plant itself differs depending on the diversity of the host, which produces different chemical constituents. An analysis of differential metabolites demonstrated that artonin E2, sanggenon F/H, kuwanon S2, sanggenon M, kuwanon D, and sanggenol L were all enriched in Morus alba-parasitizing specimens, indicating that T. chinensis absorbed these compounds by parasitizing Morus alba, thereby changing its own metabolic components. According to resource survey results, there are currently more than 150 kinds of hosts for Taxilli Herba. This wide host range creates substantial phytochemical variability in commercial material, a recognized quality-control challenge.

Other Chemical Classes

Beyond flavonoids, the following compound classes have been documented:

Phenolic acids and phenylpropanoids: These include compounds isolated from specimens growing on Morus alba, Mangifera indica, and Liquidambar formosana.
Glycosides: Glycosides are compounds in which sugars are attached to a non-sugar substance. To date, 18 glycosides have been isolated and identified from T. chinensis. Phytochemical research on the branches and leaves led to the isolation of taxilluside A–D.
Tannins and polyphenols: Including procyanidins. Procyanidin B1 was identified as an effective specific inhibitor that inhibits the Kv10.1 pathway in a concentration-dependent manner, thereby inhibiting HuH-7 and HepG2 cell migration and proliferation.
Neuroprotective compounds: The species has been reported to produce neuroprotective compounds, such as triterpenes, lectins, polysaccharides, and alkaloids.
Stilbenes: Network pharmacology and molecular docking have identified oxyresveratrol, isorhamneol, and robinetin as components exhibiting strong binding affinities for key molecular targets. Additionally, dihydromyricetin and oxyresveratrol exhibited potent inhibitory effects on xanthine oxidase (XOD), with IC₅₀ values of 0.48 and 0.68 mg·mL⁻¹ respectively.
Other functional substances: Because of its rich flavonoids, alkaloids, terpenoids, polysaccharides, and organic acids, T. chinensis has become one of the important medicinal plants in traditional Chinese medicine.

4. Established Mechanisms of Action

Anti-inflammatory Mechanisms

The anti-inflammatory pharmacological effects are closely related to the plant's traditional applications. Primarily, it inhibits the production of inflammatory factors and reduces mitochondrial oxidative stress and cyclin degradation. At a cellular level, studies in RAW 264.7 macrophage models have reported inhibition of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) production by water/ethanol extracts at concentrations around 60 mg/mL, as noted in pharmacological summary tables in the 2022 comprehensive review. Quercetin has been shown to cause inhibition of glucose, lactate, lactate dehydrogenase, pyruvate, and ATP, and increased pyruvate dehydrogenase expression in rheumatoid synoviocyte (MH7A) cells, with further confirmation that quercetin may inhibit energy metabolism and inflammatory factor secretion through the JAK1/STAT3/HIF-1α signaling pathway.

Antioxidant Mechanisms

The flavonoid-rich composition of T. chinensis underlies its antioxidant properties. DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS (2,2'-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid) free-radical scavenging activities have been documented in extracts from specimens parasitizing various hosts. The plant's polyphenols function by donating hydrogen atoms or electrons to free radicals, chelating transition metal ions, and upregulating endogenous antioxidant enzyme activities.

Antihypertensive Mechanisms

The antihypertensive pharmacological effects are closely related to the plant's traditional applications; the mechanisms involve inhibition of inflammatory factor production and reduction of mitochondrial oxidative stress. Additional proposed mechanisms include vasodilatory and direct smooth-muscle-relaxing effects attributable to flavonoid constituents, though these remain primarily characterized at the preclinical level.

Anticancer and Antiproliferative Mechanisms

The extract of T. chinensis from Casuarina equisetifolia showed inhibitory effect on the proliferation of HL-60 and K562 leukemia cells in vitro; the diethyl ether, ethyl acetate, and n-butanol fractions were identified as the active fractions against leukemia cells for the first time. However, the active ingredient and its mechanism require further investigation. Quercetin treatment in vivo significantly reduced tumor volume in P39 xenografts, revealing antitumor activity and indicating that quercetin is an attractive antitumor drug candidate. Procyanidin B1 was identified as an effective specific inhibitor that inhibits the Kv10.1 pathway in a concentration-dependent manner, thereby inhibiting HuH-7 and HepG2 hepatocellular carcinoma cell migration and proliferation.

Antibacterial Mechanisms

The compounds in the ethyl acetate extract of T. chinensis were identified by UPLC-Q-Orbitrap and analyzed by mass spectrometry. The antibacterial effect and mechanism of the active components were determined, finding for the first time that T. chinensis has a good antibacterial effect, with the ethyl acetate extract showing the best activity. Additionally, 4-indolecarbaldehyde was identified for the first time as an active component with a broad-spectrum antibacterial effect.

Hyperuricemia and Xanthine Oxidase Inhibition

In a recent study, 46 compounds were identified in the plasma of rats administered T. chinensis extract. Through network pharmacology, 10 potential active components, 10 crucial target genes, and 20 pathways were predicted to be involved in T. chinensis-mediated treatment of hyperuricemic nephropathy. Molecular docking showed that oxyresveratrol, isorhamneol, and robinetin exhibited strong binding affinities for GAPDH, PPARG, and ALB. Dihydromyricetin and oxyresveratrol exhibited potent inhibitory effects on xanthine oxidase (XOD), with IC₅₀ values of 0.48 and 0.68 mg·mL⁻¹.

5. Scientific Evidence by Area of Use

Overview of Evidence Quality

Currently, research on T. chinensis is in the preliminary stages, and further research is required to understand the active compounds present and mechanisms of action. The literature on T. chinensis is mainly based on the identification of chemical components; the components have not been thoroughly analyzed, and only simple pharmacological activity studies have been performed that were mainly focused on crude extracts and their characteristic compounds, especially quercetin. Furthermore, many active components of T. chinensis have not yet been fully investigated, nor have their mechanisms of action been elucidated. The overwhelming majority of published evidence is preclinical — consisting of in vitro cell-based assays and animal studies. Robust, randomized, controlled clinical trials in human populations are largely absent for T. chinensis as a single herb, although it appears in multi-herb traditional prescriptions that have been subjected to some clinical investigation.

Rheumatoid Arthritis and Musculoskeletal Inflammation

Traditional basis: The traditional functions of T. chinensis include "dispelling wind dampness, strengthening bones and muscles, and preventing miscarriage." Since the Eastern Han dynasty, it has been used for the treatment of rheumatoid arthritis and arthralgia.

Preclinical evidence: In vitro studies using MH7A rheumatoid synoviocytes have examined the effect of quercetin — the primary bioactive flavonoid — on inflammatory signaling. These studies concluded that quercetin's action on multiple target molecules and pathways makes it a promising treatment for cartilage injury in rheumatoid arthritis. By reducing joint inflammation, improving joint metabolic homeostasis, and decreasing immune system activation energy, quercetin inhibits the JAK1/STAT3/HIF-1α signaling pathway to improve disease status. This evidence is, however, limited to in vitro models.

Clinical evidence: The Duhuo Jisheng Decoction (DJD), of which T. chinensis is a component, has been studied in clinical settings for musculoskeletal conditions including knee osteoarthritis. However, isolating the contribution of T. chinensis specifically within a multi-herb formula is not possible from existing trial designs. No standalone clinical trials of T. chinensis for rheumatoid arthritis or arthralgia in humans were identified in the available literature. Evidence strength: in vitro and traditional use only; no human clinical trial data specific to the single herb.

Hypertension and Cardiovascular Effects

Traditional basis: T. chinensis has been used in various traditional Chinese medicine prescriptions for the treatment of hypertension and angina pectoris for many years in China.

Preclinical evidence: In vitro and animal studies suggest vasodilatory and antioxidant activities that could theoretically support blood pressure regulation. The anti-inflammatory and antioxidant mechanisms described above — particularly flavonoid-mediated inhibition of oxidative stress — are biologically plausible contributors to vascular protection. The antihypertensive pharmacological effects observed in laboratory models are considered closely related to traditional applications, as summarized in the 2022 comprehensive review.

Clinical evidence: No standalone, controlled human clinical trials specific to T. chinensis and hypertension were identified. Evidence strength: preliminary, preclinical only; no standalone human clinical data.

Threatened Abortion and Fetal Protection

Traditional basis: "Preventing miscarriage" is one of the three core classical indications of T. chinensis, and it has featured in preparations for threatened abortion since the Eastern Han dynasty. The TCM concept underlying this use is that the herb "calms the fetus" (安胎, ān tāi) by nourishing liver and kidney yin.

Scientific evidence: In addition, T. chinensis exhibits both hepatotoxicity and embryotoxicity, according to preclinical toxicology data reported in the 2022 review. This finding is directly in tension with the classical indication of fetal protection and underscores the importance of distinguishing between traditional empirical use and contemporary toxicological findings. No human clinical trials on this indication were identified. Evidence strength: traditional use documented; embryotoxicity signals from preclinical studies require attention; no human trial data.

Anticancer Activity

Preclinical evidence: Several in vitro studies have identified antiproliferative properties. Pharmacological study tables document anti-inflammatory activity in RAW 264.7 macrophage models using whole dried plant water/ethanol extracts at 60 mg/mL. The extract of T. chinensis from Casuarina equisetifolia showed inhibitory effects on HL-60 and K562 leukemia cell proliferation in vitro; however, the active ingredient and its mechanism remain to be determined. Components derived from Morus alba-parasitizing specimens can induce apoptosis and exhibit strong inhibitory activity against cancer cells, indicating potential for development into an effective anticancer drug.

Evidence strength: in vitro (cell line) studies only; no animal models with whole T. chinensis extract and no human clinical data. Highly preliminary.

Antimicrobial Activity

Study of the antibacterial effect and mechanism of T. chinensis ethyl acetate extract, identified by UPLC-Q-Orbitrap mass spectrometry, found for the first time that T. chinensis has a good antibacterial effect, with 4-indolecarbaldehyde identified as an active component with a broad-spectrum antibacterial effect. These findings are from in vitro assays. Evidence strength: preliminary, in vitro only.

Antiviral Activity

Through screening of natural products with antiviral activities, extracts of Taxillus chinensis showed promising effects against SARS-CoV in preclinical screening. This observation is derived from in vitro screening work and has not been validated in clinical studies. Evidence strength: highly preliminary, in vitro screening data only.

Hyperuricemia and Kidney Protection

A 2025 PubMed-indexed study explored the material basis of T. chinensis in treating hyperuricemic nephropathy. Forty-six compounds were identified in the plasma of rats administered the extract. Through network pharmacology, 10 potential active components, 10 crucial target genes, and 20 pathways were predicted to be involved. Dihydromyricetin and oxyresveratrol exhibited potent inhibitory effects on xanthine oxidase, with IC₅₀ values of 0.48 and 0.68 mg·mL⁻¹. Evidence strength: animal and network pharmacology study; no human clinical data.

Antihyperglycemic Activity

Pharmacological studies have demonstrated that T. chinensis possesses antihyperglycemic properties, but these are based on in vitro and animal studies. No human clinical trials on glycemic control with T. chinensis as a single herb were identified. Evidence strength: preclinical only.

Immunomodulatory Activity

Polysaccharide fractions isolated from T. chinensis have been investigated for immunomodulatory properties in preclinical models. Immunomodulatory activities of polysaccharides isolated from Taxillus chinensis and Uncaria rhyncophylla have been studied. Evidence strength: preclinical; further characterization needed.

6. Body Systems and Health Areas Associated with Taxillus chinensis

Musculoskeletal system: Rheumatoid arthritis, arthralgia, joint swelling and pain, bone and tendon strengthening.
Cardiovascular system: Hypertension, angina pectoris, arrhythmia, stroke.
Reproductive system: Threatened abortion, fetal stabilization (traditional), nourishing blood.
Hepatic and renal systems: Liver and kidney tonic (TCM); diuretic effects in preclinical models; hyperuricemic nephropathy (preclinical).
Immune system: Anti-inflammatory, immunomodulatory (preclinical).
Oncology (preclinical): Antiproliferative against leukemia and hepatocellular carcinoma cell lines in vitro.
Metabolic system: Antihyperglycemic (preclinical); xanthine oxidase inhibition relevant to gout/hyperuricemia.
Infectious disease (preclinical): Antibacterial, antiviral.

7. Dosage Forms and Dosages Reported in Studies

Bioassessments should consider the advisable effective dose, frequency of administration, and treatment duration. Standardized human dosing guidelines for T. chinensis as a single herb are not established in Western pharmacopoeial systems. The following dosages appear in primary research literature:

In vitro anti-inflammatory studies: Whole dried plant water/ethanol extracts were tested at concentrations of 60 mg/mL in RAW 264.7 macrophage models, with inhibition of NO and TNF-α production documented.
Duhuo Jisheng Decoction preparation (animal study): Three doses were soaked in water and boiled, then concentrated to yield low-dose (0.6 g/mL), medium-dose (1.2 g/mL), and high-dose (1.9 g/mL) DHJSD preparations for experimental administration. These reflect the total multi-herb decoction concentrations, not T. chinensis alone.
Traditional Chinese Pharmacopoeia: Taxilli Herba is included in the 2020 Edition of the Chinese Pharmacopoeia, which provides official dosing specifications for internal use (typically expressed as grams of dried herb per decoction), though these specific figures were not directly accessible in the sources reviewed.
Hyperuricemia nephropathy study: Forty-six compounds were identified in the plasma of rats administered with the extract, with dosing described in the experimental methodology but not specified in the abstract.

No human clinical dose-finding or dose-ranging studies for T. chinensis as a single herb were identified in the available sources.

8. Safety Considerations

Hepatotoxicity

In addition, T. chinensis exhibits both hepatotoxicity and embryotoxicity. These findings, documented in the 2022 comprehensive review published in the peer-reviewed journal Chinese Medicine, represent the most significant safety signals identified in the published literature. The hepatotoxic effects have been observed in preclinical (animal and in vitro) models; the specific compounds responsible and the dose-response relationship in humans have not been fully delineated, and clinical case reports of hepatotoxicity attributable specifically to T. chinensis were not identified in the sources reviewed.

Embryotoxicity

The preclinical finding of embryotoxicity is directly paradoxical given the classical traditional indication of "preventing miscarriage" and "calming the fetus." Clinical applications must be specified; otherwise, the herb may be misused, and the desired therapeutic effect will not be achieved. This warning is particularly salient in the context of pregnancy-related indications.

Host-Dependent Compositional Variability as a Safety Factor

Since Taxillus chinensis is a semi-parasitic plant, the complex diversity of host plants constitutes an important biological feature of Taxilli Herba. According to the results of resource surveys, there are currently more than 150 kinds of hosts for Taxilli Herba. It is difficult to distinguish specimens from different hosts based on their appearance. Host plants affect the quality of Taxilli Herba through the special relationship between hosts and the plant in terms of chemical constituents and pharmacological effects. This compositional variability means that material sourced from different hosts may carry different profiles of bioactive — and potentially toxic — compounds, complicating standardization and safety assessment.

Analysis of differential metabolites demonstrated that artonin E2, sanggenon F/H, kuwanon S2, sanggenon M, kuwanon D, and sanggenol L — all enriched components of Morus alba branches and roots — can be absorbed by T. chinensis when parasitizing Morus alba, thereby changing its own metabolic components. These transferred host compounds may carry their own biological activity, including potentially adverse effects, that would not be present in specimens from other hosts.

Absence of Established Safety Data in Humans

Many active components of T. chinensis have not yet been fully investigated, nor have their mechanisms of action been elucidated. Bioassessments should consider the advisable effective dose, frequency of administration, and treatment duration. Systematic human safety studies, including pharmacokinetic characterization and drug-interaction profiling, have not been reported in the available sources.

Drug Interactions

No peer-reviewed clinical data on pharmacokinetic or pharmacodynamic interactions between T. chinensis and pharmaceutical drugs were identified in the sources reviewed. Given that key constituents such as quercetin are known inhibitors and/or inducers of cytochrome P450 enzymes and drug transporters in other research contexts, this represents an area of acknowledged uncertainty rather than confirmed interaction.

9. Research Limitations and Evidence Gaps

The literature on T. chinensis is mainly based on the identification of chemical components; the components have not been thoroughly analyzed, and only simple pharmacological activity studies have been performed that were mainly focused on crude extracts and characteristic compounds. Many active components have not been fully investigated, nor have their mechanisms of action been elucidated. Bioassessments should also consider advisable effective dose, frequency of administration, and treatment duration.

Key gaps in the current evidence base include:

Absence of randomized controlled clinical trials assessing efficacy of T. chinensis as a single-herb intervention for any indication.
Lack of systematic human pharmacokinetic studies for its key constituents when administered as the whole herb.
Insufficient characterization of the safety profile, particularly regarding the hepatotoxicity and embryotoxicity signals observed preclinically.
Poor standardization of commercial raw material due to host plant variability affecting the type and quantity of bioactive compounds.
Reliance on network pharmacology and molecular docking — computational methods that generate hypotheses but do not confirm in vivo activity or clinical relevance.
Most in vitro studies employ isolated compounds (particularly quercetin) rather than whole-plant extracts, making extrapolation to clinical use of the crude herb uncertain.